Extrait

This is a Phase I, multicenter, open-label, dose-escalation study of DCDS4501A administered as a single agent by IV infusion to patients with relapsed or refractory hematologic malignancies. In Phase Ib, patients will receive DCDS4501A in combination with rituximab.

Critère d'inclusion

• Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

Pays

• Canada
• France
• Netherlands
• United States

Liens

• nct
• ictrp